Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair

Executive Summary

Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.

Advertisement

Related Content

Hikma's CRL Proves GSK's Witty Was Right: Generic Advair Is Hard
Teva To Divest Women's Health, Some Oncology As CEO Search Proceeds
Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns
Mylan Takes Issue With FDA Over 'Major' CRL For Advair Generic
Express Scripts Value-Based Program To Leverage Generic Advair
Mylan’s Generic Advair Delay Gives Leverage To Rivals
Teva CEO Steps Down While An Integration Hangs In The Balance
Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair
Teva Changes Its Tune On Substitutable Generic Advair
Teva Has Grand Ambitions In Respiratory Disease, With An Eye On Advair

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel